ADAP - Adaptimmune Therapeutics PLC

0.2653
-0.001   -0.490%

Share volume: 474,224
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.27
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 35%
Dept financing 22%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.96%
1 Month
28.79%
3 Months
-55.03%
6 Months
-64.01%
1 Year
-76.93%
2 Year
-81.32%
Key data
Stock price
$0.27
P/E Ratio 
0.00
DAY RANGE
$0.26 - $0.28
EPS 
-$0.05
52 WEEK RANGE
$0.20 - $1.48
52 WEEK CHANGE
-$76.93
MARKET CAP 
137.844 M
YIELD 
N/A
SHARES OUTSTANDING 
255.745 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$628,670
AVERAGE 30 VOLUME 
$1,896,829
Company detail
CEO: Adrian Rawcliffe
Region: US
Website: adaptimmune.com
Employees: 490
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)

Recent news
loading